



## Gynecologic Cancer InterGroup (GCIg)

# Ovarian Cancer Committee

Friday, November 07, 2014, 1:00pm – 2:30pm  
Bridge 5 Room, Crowne Plaza Hotel, Melbourne

**Chair: P.Harter Co-Chair: A.Gonzalez**

Harmonization liaisons: Carty/Stonebraker (ops); Embleton/Brady (Stats)

*Please sign-in on attendance forms*

### AGENDA

- Welcome & Introductions (COI disclosures)
- Closed/ongoing trials: (30')
- Planned trials (15' each trial including discussion)
  - Stics and Stones: Prospective Assessment of Aspirin in Prevention of High Risk Ovarian Cancer: NCIC CTG (S. Lheureux)
  - Neo Trial: A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Ovarian cancer: Princess Margaret Consortium (M. Wilson)
  - eVolve Trial: Randomized comparison of chemotherapy vs Cedarinib/olaparib following progression on a parp inhibitor: Princess Margaret Consortium. (S. Lheureux)
  - AVANOVA: NSGO (M. Mirza)
- Scientific discussion – BRCA & PARP around the world

- Counseling and testing within GCIG (20')
  - Harmonization Committee survey results: J. Bryce
  - PMH survey results: S. Lheureux
- Offering testing to every OC patient in Edinburgh – first experiences (15'): C. Gourley
- Ongoing and planned PARP-trials (15'): M. Mirza

Adjourn